This is a working overview of Selank, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-23. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Typical purity report | 95% or higher by HPLC | Area percentage at 214 nm |
| Identity confirmation | Mass spectrometry | Electrospray or MALDI |
| Powder storage | -20 C, desiccated | Protect from light |
| Solution storage | 2-8 C short term | Freeze aliquots for longer |
| Quality document | Certificate of analysis | States method and value |
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Considered radicals by another moderate current of the PCC, they used terrorism to intimidate authorities of the prison system and were withdrawn from leadership in November 2002, when the leadership was taken over by the current leader of the organization, Marcos "Marcola" Willians Herbas Camacho. Marcola would eventually order the deaths of Geleião and Cesinha for having testified to the police, as well as for allegedly leaving the faction and creating a splinter group called the "Terceiro Comando da Capital" (Third Capital Command, TCC), which is now considered to be defunct.
== Early life and education == Born in Thuine, Lower Saxony, he studied mathematics and physics at the University of Göttingen. He received his Ph.D. in 1988 at Yale University where he worked in the group of John Fenn, who was later awarded the Nobel Prize in Chemistry.
== Side effects == The usual dose of 350 mg is unlikely to elicit prominent side effects other than somnolence, and mild to significant euphoria or dysphoria, but the euphoria is generally short-lived due to carisoprodol's fast metabolization into meprobamate and other metabolites, and is most likely due to carisoprodol's inherent, potent anxiolytic effects, which are far stronger than those of meprobamate, which is often misblamed for the drug-seeking associated with carisoprodol. Carisoprodol has a qualitatively different set of effects from meprobamate (Miltown). The medication is well tolerated and without adverse effects in most patients for whom it is indicated, but in some patients, and/or early in therapy, it can have the full spectrum of sedative side effects and impair the patient's ability to operate a firearm, motor vehicles, and other machinery of various types, especially when taken with medications containing alcohol, in which case alternative medications are considered. The intensity of the side effects of carisoprodol tends to lessen as therapy continues, as with many drugs. Other side effects include dizziness, clumsiness, headache, fast heart rate, upset stomach, vomiting, and skin rash. There are 368 drugs known to interact with carisoprodol, including 28 major drug interactions.
=== Classification === Neanderthals can be classified as a unique species as H. neanderthalensis, though some authors argue expanding the definition of H. sapiens to include other ancient humans, with combinations such as H. sapiens neanderthalensis. The latter opinion has generally been justified using Neanderthal genetics, as well as inferences on the complexity of Neanderthal behaviour based on the archaeological record. While there seems to have been some genetic contact between these two groups, there are potential indicators of hybrid incompatibility, which if true could justify species distinction. The crux of the issue lies in the vagueness of the term "species" (the species problem). Among identified archaic humans, Neanderthals are most closely related to Denisovans based on nuclear DNA (nDNA) analyses. Denisovans are an enigmatic group of Late Pleistocene humans only recognisable by a genetic signature rather than anatomical landmarks. Likely due to more recent interbreeding episodes, the mitochondrial DNA (mtDNA, passed down maternally) and Y-chromosome DNA (passed down paternally) are more similar between Neanderthals and modern humans than between Neanderthals and Denisovans. Similarly, 430,000 year old fossils from the Sima de los Huesos are more closely related to Neanderthals in their nDNA, but their mtDNA aligns more closely with Denisovans. A 2021 phylogeny of some Middle Pleistocene and Neanderthal fossils using tip dating:
Sources: en.wikipedia.org
=== Season 2 === Season 2 opens with Radhi adjusting to life outside the hospital after stepping away from her duties, while Reena struggles under the new leadership of Arjun, the recently appointed CEO. Encouraged by her children and her own sense of purpose, Radhi reclaims her role. The story follows Radhi and Reena dealing with their past, fuelled by the arrival of Reena's biological father and Radhi's past love interest, Dr. Vijay. Soon, both Reena and Vijay get to know the truth about each other but very soon the former meets with an accident.
== Decay properties == Bismuth-209 was long thought to have the heaviest stable nucleus of any element, but in 2003, a research team at the Institut d'astrophysique spatiale in Orsay, France, discovered that 209Bi undergoes alpha decay with a half-life now given more precisely as 2.01×1019 years (20.1 quintillion years), over 109 times longer than the estimated age of the universe. The heaviest nucleus considered to be stable is now lead-208 and the heaviest stable monoisotopic element is gold (gold-197). Theory had previously predicted a half-life of 4.6×1019 years. It had been suspected to be radioactive for a long time. The decay produces a 3.14 MeV alpha particle plus thallium-205.
Such challenges can include the difficulty associated with recycling different electrolyte compositions, removing side products accumulated from electrolyte decomposition during its runtime, and removal of electrolyte adsorbed onto the electrodes. Due to these challenges, current pyrometallurgical methods of Li-ion battery recycling forgo electrolyte recovery, releasing hazardous gases upon heating. However, due to high energy consumption and environmental impact, future recycling methods are being directed away from this approach.
Sources: en.wikipedia.org
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.
Dry powder is kept frozen, desiccated, and shielded from light. Dissolved material is aliquoted and frozen to limit freeze-thaw cycles. Short-term refrigerated storage is common for working solutions.
Russia registers it as a prescription nasal product. Most other markets classify it as a research chemical with no approved medical use. Oversight of purity and labeling is consequently minimal in those markets.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.